scholarly journals No Difference on Adherence Between Immediate-Release Versus Extended-Release Dopamine Agonists in Uninsured Subjects with Parkinson's Disease

2015 ◽  
Vol 3 (1) ◽  
pp. 68-72 ◽  
Author(s):  
Lisette Bazán-Rodríguez ◽  
Amin Cervantes-Arriaga ◽  
Rodrigo Llorens-Arenas ◽  
Humberto Calderón-Fajardo ◽  
Mayela Rodríguez-Violante
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Agonists ◽  
Extended Release ◽  
Immediate Release

scholarly journals Pramipexole and its Extended Release Formulation for Parkinson's Disease

2011 ◽  
Vol 3 ◽  
pp. JCNSD.S5210 ◽  
Author(s):  
Paul S. Fishman
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Immediate Release ◽  
Motor Fluctuations ◽  
Release Formulation ◽  
Extended Release Formulation ◽  
Release Preparation ◽  
Early Parkinson’S Disease ◽  
Release Form

Pramipexole has been a widely used dopamine agonist for the last decade. Recently an extended release formulation of pramipexole has been introduced as both monotherapy for patients with early Parkinson's disease as well as for patients with more advanced disease, as an adjunct to L-DOPA. Along with the enhanced patient compliance seen with once a day dosing, there are other potential advantages of extended release preparations of dopamine agonists. Patients initiated on pramipexole have a lower incidence of developing motor fluctuations including dyskinesia than those initiated on L-DOPA. Pramipexole requires a prolonged dose titration compared to L-DOPA, and generally does not have the efficacy of L-DOPA. The extended release form of pramipexole shows comparable mean and peak serum levels with once a day dosing as seen with three times a day dosing of the immediate release preparation. The extended release preparation has been studied in randomized multicenter clinical trial against both placebo and the immediate release preparation in the setting of early Parkinson's disease as monotherapy and in more advanced patients with motor fluctuations on L-DOPA. In both settings the extended release preparation was superior to placebo and comparable to the immediate release form in efficacy with a similar side effect profile including nausea, sleepiness, leg edema, dyskinesias, hallucinations and impulse control disorders.

scholarly journals Dopamine Dysregulation Syndrome in Parkinson’s Disease Patients with Unsatisfactory Switching from Immediate to Extended Release Pramipexole: A Further Clue to Incentive Sensitization Mechanisms?

2013 ◽  
Vol 27 (4) ◽  
pp. 563-566 ◽  
Author(s):  
Paolo Solla ◽  
Antonino Cannas ◽  
Marta Corona ◽  
Maria Giovanna Marrosu ◽  
Francesco Marrosu
Keyword(s):  
Parkinson’S Disease ◽  
At Risk ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Early Recognition ◽  
Immediate Release ◽  
Behavioral Disorder ◽  
Behavioral Disturbance ◽  
Careful Monitoring ◽  
Dopamine Dysregulation Syndrome

A small proportion of patients with Parkinson’s disease (PD), chronically under dopamine replacement therapy, may undergo an addiction-like behavioral disturbance, named dopamine dysregulation syndrome (DDS). This behavioral disorder is characterized by the increase of doses beyond those required for motor control, and its management remains difficult; thus, early recognition and careful monitoring of at-risk individuals are crucial. We report the cases of two PD patients with a previous unsatisfactory switching from an immediate release (IR) to an extended release (ER) pramipexole formulation who developed DDS. PD patients unsatisfactorily switched from an IR to an ER formulation of dopamine agonists should be considered as at-risk individuals for DDS development.

scholarly journals Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease

2010 ◽  
Vol 2010 ◽  
pp. 1-7 ◽  
Author(s):  
Wolfram Eisenreich ◽  
Bernd Sommer ◽  
Sebastian Hartter ◽  
Wolfgang H. Jost
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Agonist ◽  
Extended Release ◽  
Plasma Concentrations ◽  
Safety Data ◽  
Immediate Release ◽  
Efficacy And Safety ◽  
Release Formulation ◽  
Extended Release Formulation

Pramipexole, the most commonly prescribed dopamine agonist worldwide, meanwhile serves as a reference substance for evaluation of new drugs. Based on numerous clinical data and vast experiences, efficacy and safety profiles of this non-ergoline dopamine agonist are well characterized. Since October 2009, an extended-release formulation of pramipexole has been available for symptomatic treatment of Parkinson's disease. Pramipexole administration can be cut down from three times to once a day due to the newly developed extended-release formulation. This is considerable progress in regard to minimizing pill burden and enhancing compliance. Moreover, the 24 h continuous drug release of the once-daily extended-release formulation results in fewer fluctuations in plasma concentrations over time compared to immediate-release pramipexole, given three times daily. The present study summarizes pharmacokinetics and all essential pharmacological and clinical characteristics of the extended-release formulation. In addition, it provides all study data, available so far, with regard to transition and de-novo administration of extended-release formulation for patients with Parkinson's disease. It further compares efficacy and safety data of immediate-release pramipexole with the extended-release formulation of pramipexole.

Sign in / Sign up

Export Citation Format

Share Document